Lipocine Inc
LPCN
Get informed when a big investor buys or sells
+ FollowMarket Cap$13.06M
Close$
$0.91
58.6% downside
Current Fair Value
58.6% downsideOvervalued by 58.6% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $13.06 Million |
|---|---|
| Enterprise Value | $8.36 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-1.77 |
| Beta | 0.5 |
| Outstanding Shares | 6,795,000 |
Return
| Return on Equity | -50.08% |
|---|---|
| Return on Assets | -45.09% |
| Return on Invested Capital | 23.88% |
Valuation & Multiples
| P/E Ratio | -1.34 |
|---|---|
| PEG | -1.38 |
| Price to Sales | - |
| Price to Book Ratio | 0.73 |
| Enterprise Value to Revenue | 4.18 |
| Enterprise Value to EBIT | 1.53 |
| Enterprise Value to Net Income | -1 |
| Total Debt to Enterprise | 0.04 |
| Debt to Equity | 0.01 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
May 14, 2026
EPS Estimate
$-0.60
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationNext Earnings Call
Expected Date
August 4, 2026
EPS Estimate
$-0.47
Average shareholder expectationRevenue Estimate
$156,500
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | - |
| Total Puts | - |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 57.23%▲ 27.12% |
|---|---|
| Total Invested | $24.92M▲ 90.36% |
| Investors Holding | 46▲ 20.00% |
ESG Score
No data
About Lipocine Inc
CEO: Mahesh Patel Lipocine Inc. is a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders using its proprietary drug delivery technologies. Lipocine's clinical development pipeline includes: TLANDO, LPCN 1144, TLANDO XR, L...